Posts Tagged ‘Blood Pressure Monitor’

ASX Company News: AtCor Medical Enters Distribution Agreement With SunTech Medical

Thursday, July 28th, 2011

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressures and arterial stiffness noninvasively, and SunTech Medical Inc., a leader in noninvasive blood pressure products and technologies, announced that they have entered into an exclusive, multi-year worldwide clinical trials distribution and data management agreement.

SunTech technology is especially well-suited for clinical trials, and features the patented OrbitTM blood pressure cuff, which is specifically designed for ambulatory wear, thus promoting patient comfort and compliance and improving data yield. This expansion of core lab services offers pharmaceutical companies, CRO’s and other researchers from a single source, greatly improved reliability and quality of information on the effects of drugs on central and peripheral hemodynamics-critically important data in identifying drug benefits as well as potential patient risk. AtCor Medical provides comprehensive trials support services: technology sales and leasing, trial site training, data quality assurance and best-in-class data management, using the AtCor WISDOM system. The WISDOM system allows real-time data quality assurance through secure, instantaneous transmission of data from the clinical trials site to AtCor’s data management center.

“We are delighted to be working with SunTech”, said Duncan Ross, AtCor Medical CEO. “This is an important addition to our portfolio. It will further enhance our relationship with key pharmaceutical customers and build on the strong business fundamentals we have established in the clinical trials market. With this new offering, clinical trials customers can choose from an expansive portfolio that includes noninvasive central blood pressure assessment, pulse wave velocity measurement, heart rate variability testing and ambulatory blood pressure monitoring, all backed by AtCor Medical’s best-in-class support services.”

For over twenty years, SunTech Medical has been the preeminent supplier of clinical grade blood pressure monitoring products and technologies. SunTech produces the leading cardiac stress test blood pressure monitor and is the world’s foremost manufacturer of ambulatory blood pressure monitoring (ABPM) products. SunTech Medical also offers solutions for in-office BP monitoring as well as a complete line of blood pressure cuffs designed for general and specific applications. AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively.

www.atcormedical.com

http://www.traderdealer.com.au/Fundamentals/acg

Post to Twitter

ASX Company News: AtCor Medical Secures $1.28 million Contract Extension

Wednesday, December 22nd, 2010

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The US$1.28 million contract is with an existing AtCor customer and will expand the use of SphygmoCor in a current trial.

Duncan Ross, CEO of AtCor Medical said, “We are very pleased to continue to expand our relationship with this important customer. Our strong deal flow in the pharma sector further reinforces AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients. Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood pressure as an independent predictor and critical measurement. This mounting body of evidence helps to drive our sales to pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice”.

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals.

www.atcormedical.com

http://www.traderdealer.com.au/Fundamentals/acg

Post to Twitter

ASX Company News: AtCor Medical Secures Fourth Contract

Monday, October 18th, 2010
AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which
measures central blood pressures and arterial stiffness noninvasively, today announced that it has
signed a new agreement to supply SphygmoCor systems and clinical trial support services to a
major international pharmaceutical company. The US$0.8m contract is with an existing AtCor
customer.
Duncan Ross, CEO of AtCor Medical said, “This contract is AtCor’s fourth since US healthcare
reform legislation was signed among a number of contracts being negotiated with pharmaceutical
and biopharmaceutical companies. This transaction further demonstrates the rebounding activity
in the pharmaceutical trial sector and confirms AtCor’s market position as the leading provider of
noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also
shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through
expanded business with long-term clients.
Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood
pressure as a measurement. This mounting body of evidence helps to drive our sales to
pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice.
Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in
assuring drug safety. It is equally important in patient care.”
About AtCor Medical
AtCor Medical develops and markets products for the early detection of cardiovascular risk and
management of cardiovascular disease. Its technology allows researchers and clinicians to
measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly
identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which
cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor®
systems are currently in use worldwide at major medical institutions, research institutions and in
various clinical trials with leading pharmaceutical companies. The company’s technology has been
featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has
operations in Australia, the United States, and Europe. For further information, please visit our web
site at www.atcormedical.com.
For further information, please contact:

AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The US$0.8m contract is with an existing AtCor customer.

Duncan Ross, CEO of AtCor Medical said, “This contract is AtCor’s fourth since US healthcare reform legislation was signed among a number of contracts being negotiated with pharmaceutical and biopharmaceutical companies. This transaction further demonstrates the rebounding activity in the pharmaceutical trial sector and confirms AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients.

Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood pressure as a measurement. This mounting body of evidence helps to drive our sales to pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in assuring drug safety. It is equally important in patient care.”

www.atcormedical.com

http://www.traderdealer.com.au/Fundamentals/acg

Post to Twitter